The content on this site is intended for healthcare professionals only
Dr Timothy Whelan presents LUMINA study findings, which showed based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely.
He discusses the methodology and results of the study.
The LUMINA study enrolled participants whose biomarker screening results showed that 13.25% or less of the tumour cells had the protein marker, Ki67, which is associated with cancer cell proliferation and is consistent with the luminal A breast cancer subtype.
The patients in the study will continue to be followed for up to 10 years for effects on long term recurrence and survival.
Watch our interview with Dr Whelan here
Watch Dr Speers comment on the study here
Watch Dr Bishal Gyawali comment on the study here
Read our news story about the study here
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
